Cargando…
A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507475/ https://www.ncbi.nlm.nih.gov/pubmed/32995132 http://dx.doi.org/10.1002/advs.202001424 |
_version_ | 1783585234793529344 |
---|---|
author | Qi, Yu Liu, Yanli Yu, Bingran Hu, Yang Zhang, Nasha Zheng, Yan Yang, Ming Xu, Fu‐Jian |
author_facet | Qi, Yu Liu, Yanli Yu, Bingran Hu, Yang Zhang, Nasha Zheng, Yan Yang, Ming Xu, Fu‐Jian |
author_sort | Qi, Yu |
collection | PubMed |
description | Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly expressed on the surface of hepatocellular carcinoma (HCC) cells. Herein, a lactose‐derived branched cationic biopolymer (LBP) with plentiful reducible disulfide linkages and hydroxyl groups is proposed as a potential delivery vector of CRISPR/Cas9 system for efficient genome editing in vivo to treat orthotopic HCC. LBP is synthesized via a facile one‐pot ring‐opening reaction. LBP possesses excellent compacting ability, degradability, biocompatibility, gene transfection performances, and HCC‐targeting ability. LBP‐mediated delivery of classical pCas9‐survivin, which can target and knockout survivin oncogene, produces efficient gene editing performances, and superb anti‐cancer activities in orthotopic HCC mouse models. This study provides an attractive and safe strategy for the rational design of CRISPR/Cas9 delivery system. |
format | Online Article Text |
id | pubmed-7507475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75074752020-09-28 A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma Qi, Yu Liu, Yanli Yu, Bingran Hu, Yang Zhang, Nasha Zheng, Yan Yang, Ming Xu, Fu‐Jian Adv Sci (Weinh) Full Papers Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly expressed on the surface of hepatocellular carcinoma (HCC) cells. Herein, a lactose‐derived branched cationic biopolymer (LBP) with plentiful reducible disulfide linkages and hydroxyl groups is proposed as a potential delivery vector of CRISPR/Cas9 system for efficient genome editing in vivo to treat orthotopic HCC. LBP is synthesized via a facile one‐pot ring‐opening reaction. LBP possesses excellent compacting ability, degradability, biocompatibility, gene transfection performances, and HCC‐targeting ability. LBP‐mediated delivery of classical pCas9‐survivin, which can target and knockout survivin oncogene, produces efficient gene editing performances, and superb anti‐cancer activities in orthotopic HCC mouse models. This study provides an attractive and safe strategy for the rational design of CRISPR/Cas9 delivery system. John Wiley and Sons Inc. 2020-07-21 /pmc/articles/PMC7507475/ /pubmed/32995132 http://dx.doi.org/10.1002/advs.202001424 Text en © 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Papers Qi, Yu Liu, Yanli Yu, Bingran Hu, Yang Zhang, Nasha Zheng, Yan Yang, Ming Xu, Fu‐Jian A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title | A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title_full | A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title_fullStr | A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title_full_unstemmed | A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title_short | A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma |
title_sort | lactose‐derived crispr/cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507475/ https://www.ncbi.nlm.nih.gov/pubmed/32995132 http://dx.doi.org/10.1002/advs.202001424 |
work_keys_str_mv | AT qiyu alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT liuyanli alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT yubingran alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT huyang alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT zhangnasha alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT zhengyan alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT yangming alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT xufujian alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT qiyu lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT liuyanli lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT yubingran lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT huyang lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT zhangnasha lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT zhengyan lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT yangming lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma AT xufujian lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma |